United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $548.69, for a total transaction of $5,212,555.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,229,077.97. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $6.51 during trading hours on Thursday, reaching $543.39. The company had a trading volume of 272,743 shares, compared to its average volume of 494,850. The business has a fifty day moving average price of $562.63 and a 200-day moving average price of $525.08. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $23.07 billion, a PE ratio of 20.06, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the company earned $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 26.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Finally, UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Torren Management LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.